Oral vs Injectable Sildenafil: Route, Form & Use Context

Oral and Injectable Sildenafil: Basic Comparison

Both routes deliver sildenafil as the active moiety, but their pharmaceutical forms, systemic input and labeled use contexts differ.

Oral sildenafil includes products such as tablets and oral suspensions. Current U.S. injectable sildenafil is represented by REVATIO injection, a clear, colorless, sterile, ready-to-use intravenous solution.

The most useful comparison therefore combines route pharmacokinetics with the actual product label rather than treating injection as merely a faster version of an oral sildenafil product.

Oral Administration vs Parenteral Administration

Oral sildenafil enters the gastrointestinal tract before crossing into the systemic circulation. Dissolution or dispersion, gastrointestinal conditions, absorption and presystemic metabolism can all influence the early concentration-time profile.

REVATIO injection is more specific than the broad term parenteral: current labeling describes intravenous bolus administration. It therefore bypasses gastrointestinal absorption and the oral first-pass input pathway.

This does not eliminate later distribution, metabolism or elimination. Once systemically available, sildenafil from either route undergoes the same core sildenafil-specific disposition pathways.

Formulation Differences

Route determines substantial formulation requirements. Oral sildenafil products can be manufactured as tablets, oral films or suspensions, whereas REVATIO injection must satisfy sterile intravenous-product requirements.

Current REVATIO injection is supplied as a clear, colorless, sterile, ready-to-use solution in a single-dose vial. The vial contains 10 mg sildenafil in 12.5 mL, corresponding to a concentration of 0.8 mg/mL.

Each milliliter contains sildenafil citrate equivalent to 0.8 mg sildenafil, together with dextrose and water for injection. These characteristics are specific to the injection product and differ fundamentally from oral formulation excipients and handling.

Absorption Is a Major Route Difference

Absorption is central to oral sildenafil pharmacokinetics. Current labeling describes sildenafil as rapidly absorbed after oral administration, but systemic concentrations still develop over time rather than appearing instantaneously.

REVATIO injection eliminates that gastrointestinal absorption step because sildenafil is placed directly into the systemic circulation by intravenous administration.

This distinction is the main reason oral absorption metrics should not simply be copied onto the injectable product. Detailed oral uptake mechanisms remain on the sildenafil absorption page.

Bioavailability and Route Context

Current sildenafil labeling reports a mean absolute oral bioavailability of approximately 41%, with a reported range of 25% to 63%. That value reflects the net fraction of an oral dose reaching systemic circulation unchanged after absorption and presystemic loss.

Intravenous administration bypasses those oral barriers by placing the administered drug directly into systemic circulation. The oral 41% value therefore should not be transferred to REVATIO injection.

This route distinction also explains why milligram amounts cannot be compared as though oral and IV doses delivered identical parent-drug input. The concept of absolute and relative bioavailability is covered on the sildenafil bioavailability page.

How Route Changes the Concentration-Time Profile

The early concentration-time profile differs because oral sildenafil has an absorption phase while an IV bolus creates direct systemic input.

For fasted oral sildenafil, current labeling reports Tmax values of 30 to 120 minutes, with a median of approximately 60 minutes. That Tmax measures the time required for the oral concentration curve to reach its observed peak.

An IV bolus does not have the same absorption-defined Tmax. Comparing oral and IV curves therefore requires route-specific interpretation rather than simply comparing the same PK labels across both products.

The broader principles of profile interpretation are covered on the sildenafil concentration-time page.

Route Changes Entry, Not the Identity of Sildenafil

After sildenafil reaches systemic circulation, changing the route does not change the identity of the parent molecule. Oral and intravenous sildenafil enter the same general distribution and metabolic pathways.

Current REVATIO labeling describes metabolism predominantly through CYP3A, with CYP2C9 as a minor pathway, and formation of the active N-desmethyl metabolite. Those processes remain relevant after either oral or intravenous administration.

The label also states that after either route sildenafil-related material is excreted as metabolites, predominantly through feces and to a lesser extent through urine. Detailed biotransformation remains on the sildenafil metabolism page.

Why Label Context Is Central to This Comparison

The same active drug can be approved in products with different indications, routes, strengths and populations. Route alone therefore cannot establish clinical interchangeability.

Oral sildenafil spans several current U.S. product contexts, including erectile-dysfunction and pulmonary-arterial-hypertension products. REVATIO injection, by contrast, belongs to the REVATIO WHO Group I PAH framework.

Current labeling provides intravenous dosage information specifically for adults. Pediatric REVATIO dosing in the current label is oral, which is another reason the injection should not be treated as a universal alternative to every oral sildenafil product.

Revatio and Injectable Sildenafil Context

REVATIO provides the key U.S. regulatory context for sildenafil injection. Current labeling identifies REVATIO injection as a 10 mg/12.5 mL intravenous product within the treatment framework for WHO Group I pulmonary arterial hypertension.

The product's original 2009 FDA development context was narrower: the injection was reviewed for continued sildenafil treatment in PAH patients already receiving oral REVATIO who were temporarily unable to take oral medication.

Current labeling no longer presents that historical wording as a separate limitation in the Indications section. Instead, it lists adult intravenous dosage directly within the current REVATIO PAH prescribing framework. Historical approval context and current label wording should therefore be kept distinct.

The broader relationship between sildenafil and the PAH brand is covered on the sildenafil and Revatio page.

Injectable Sildenafil Is Not an ED Route Comparison

A search for oral versus injectable sildenafil can easily be misread as a choice between two administration routes for erectile dysfunction. Current U.S. labeling does not support that framing.

Oral sildenafil has approved ED product contexts, whereas REVATIO injection belongs to PAH labeling. The existence of an IV sildenafil product does not create an FDA-labeled injectable route for erectile dysfunction.

The correct comparison is therefore pharmaceutical and regulatory: how oral and IV sildenafil differ in input, formulation and product setting.

Clinical Setting Can Differ Substantially

Many oral sildenafil products are designed for outpatient self-administration according to their applicable prescriptions and labels. Their administration does not inherently require an intravenous clinical procedure.

REVATIO injection is a sterile IV bolus formulation, which creates a fundamentally different administration environment and professional-handling context.

The difference is not simply convenience. Intravenous administration has route-specific preparation, access and administration requirements that do not apply to routine oral dosage forms.

Food Effects Apply Differently by Route

Food can alter oral sildenafil pharmacokinetics because meals can change gastrointestinal absorption. Current labeling reports that a high-fat meal delays mean oral Tmax by about 60 minutes and lowers mean Cmax by about 29%.

Those findings are specific to oral absorption. REVATIO injection bypasses the gastrointestinal tract, so a meal cannot alter IV sildenafil through the same absorption mechanism.

This does not imply that every other physiological variable disappears with intravenous use; it means specifically that oral food-effect mechanisms are not part of IV drug input. Detailed meal data remain on the sildenafil food effects page.

Handling and Product Requirements Differ

Oral and IV sildenafil have distinct storage and handling requirements because their dosage forms are fundamentally different.

Current REVATIO injection is a sterile, ready-to-use single-dose solution. It is stored at controlled room temperature, and any unused portion of the vial is discarded.

Oral products have their own requirements: tablets have solid-product storage instructions, while oral suspension has separate preparation and storage rules. Route comparison therefore should not substitute one product's handling instructions for another.

Why Oral and Injectable Sildenafil Should Not Be Assumed Interchangeable

Shared active ingredient does not establish milligram-for-milligram or product-for-product interchangeability. Oral and IV routes create different systemic input, and the products can belong to different indication and population contexts.

Current REVATIO labeling provides a specific bridge between the routes: 10 mg REVATIO injection is predicted to provide the pharmacological effect of sildenafil plus its N-desmethyl metabolite equivalent to a 20 mg oral dose.

That relationship is a labeled pharmacological prediction for REVATIO. It should not be generalized into a universal oral-to-IV conversion formula for other sildenafil products or indications.

Where Oral and Injectable Forms Fit in the Sildenafil Formulation Map

Current U.S. sildenafil dosage forms extend beyond a simple tablet-versus-injection comparison. They include conventional tablets, oral film, powder for oral suspension, ready-to-use oral suspension and REVATIO injection.

Those forms do not all share the same indication, population or administration setting. A formulation map is therefore more useful when route and product identity remain attached to each dosage form.

The broader landscape is covered on the sildenafil formulations page.

How to Interpret Oral vs Injectable Sildenafil

The most informative oral-versus-IV comparison separates three layers: systemic input, formulation and regulatory context.

At the PK level, oral sildenafil has incomplete absolute bioavailability and an absorption-defined Tmax, while IV sildenafil bypasses gastrointestinal absorption and oral first-pass input. At the product level, REVATIO injection is a sterile 0.8 mg/mL single-dose IV formulation.

At the label level, current REVATIO provides the specific adult PAH relationship of 10 mg IV versus a predicted pharmacological effect equivalent to 20 mg oral. That does not make the products freely interchangeable and does not create an injectable ED route.